Consistently, treatment with the MAPK inhibitor U0126 abolished the interaction between ERK and TRIM63, and inhibited TRIM63 phosphorylation in melanoma cells carrying BRAF V600E (Fig. 2O, Q). Here, BRAF is linked to melanoma.